

# Index

- A $\beta$  Amyloidosis, 124
- A $\beta$  deposition
  - cholinergic-amyloid fusion hypothesis for, 411–421
  - cortical cholinergic lesion and, 411–421
- A $\beta$ -derived diffusible neurotoxin ligands (ADDLs), 293
- Aberrant motor behavior, 3
- A $\beta$ -induced toxicity, resveratrol
  - neuroprotective effects against, 293
- A $\beta$  vaccine, 124
  - in AD mouse model, 265–271
  - gut immune system and advantage of, 269–270
  - immune responses to, 268
  - mechanism of, 271
  - mediated meningoencephalitis, 268–269
  - production of, 266–267
  - vaccination and tissue examinations, 267–268
- Acetylcholine, 54
- Acetylcholine (ACh) synthesis, 403–404, 407
- Acetylcholinesterase enzyme (AChE), 404–405, 414, 416, 439, 442, 446, 449, 452–458
  - A $\beta$  effect on levels of, 430–431
  - expression in AD brain, 429–435
  - inhibitors and cholinergic deficiency, 433
  - multiple isoforms of, 429–430
- Acetylcholinesterase enzyme inhibitors (AChEIs)
  - effect on A $\beta$ PP expression and metabolism, 441–442
  - gene expression modulation, 442–443
- Activated microgila in PD, 91–95, 117–119
  - damaged dopamine neurons, 92
  - neuroprotective and neurotoxic subtypes, 94–95
  - in putamen, 92–93
  - in substantia nigra and brain regions, 92–93, 117
- Activities of Daily Living Scale (ADCS-ADL), 5
- Acute akinesia in Parkinson's disease patients, 31–34
- ADAM10, 442
  - promoter activity, 371–373
  - as  $\alpha$ -secretase, 369–370, 394
- Adeno-associated virus vector (AAV) vaccine
  - in AD mouse model, 265–271
  - gut immune system and advantage of, 269–270
  - immune responses to, 268
  - production of, 266–267
  - vaccination and tissue examinations, 267–268
- Adrenal chromaffin cells, 51
- Aging, free radical theory, 192
- Akinesia, 25, 31, 35
- Alcohol dehydrogenase (ADH), 362
- Aldehyde dehydrogenase (ALDH), 362
- Aldehyde hydrogenase, 362
- Alzheimer Disease Assessment Scale-Cognitive Section (ADAS-cog), 4–5
- Alzheimer Disease Collaborative Study-Clinical Global Impression of Change (ADCS-CGIC), 5
- Alzheimer's APP transgenic mice
  - immunization with phage-ScFv against  $\beta$ -amyloid peptide, 274–275
  - targeting  $\beta$ -amyloid plaques with phage anti-A $\beta$  ScFv, 275–277
- Alzheimer's-associated neurodegeneration, decreased ProBDNF as cause, 279–281

- Alzheimer's disease (AD), 1, 41–41, 81, 98  
 AGD and TSAs relation in, 375–379  
 amyloid cascade hypothesis, 298–299  
 amyloid fragments in, 171–173  
 $\beta$ -amyloid role in pathophysiology, 439–443  
 ApoE related  
   cholesterol levels in, 357–358  
   GOT, GPT, and GGT activities in, 359  
   plasma triglyceride levels in, 357–358  
 A $\beta$  deposition and neuroinflammatory response in, 114–115  
 BDNF down-regulation  
   and functional deficits, 281  
   loss of synaptic and neuronal function, 279–281  
   and pathophysiology, 280  
 biological complexity in treatment, 439–443  
 biomarkers for, 169–173  
 cell cycle reentry in, 138–139  
 CERAD criteria, 139  
 cholesterol transport and production in, 211–217  
 cholinergic changes in, 393–394, 403–405, 407, 420  
 cholinergic markers in, 404, 420  
 cholinergic neurites in, 432  
 CSF biomarkers, 172  
 CYP2D6 polymorphisms in, 363–364  
 dysfunction of proteomics-identified  $\beta$ (1-42)-induced oxidized proteins, 160  
 G $\alpha$  as seed for amyloid, 387–391  
 genetic factors, 197–198  
 glutamatergic changes in, 405–407  
 inflammation and pathological cascade in, 116–117  
 intraneuronal A $\beta$ , 297–301  
 Khachaturian criteria for, 139  
 lifestyle-related factors and, 208–209  
 lipids, 222–223  
 mechanistic hypothesis of, 191  
 midlife risk factors for dementia, 207  
 mitotic abnormalities and signaling, 194–195  
 $\alpha$ 7 nAChRs, 431–432, 434  
 neuroinflammation and regenerative pathways in, 115–116  
 neuronal death in, 133–134  
 neuropathology of, 429  
 oxidative insult and neuronal survival role, 133–142  
 A $\beta$ , tau, and  $\alpha$ -synuclein function against, 140–142  
 genetic mutations and risk factors, 135–136  
 oxidatively modified brain proteins identification, 151–153  
 oxidative stress  
   with genetic mutations and risk factors, 135–138  
   and oxidative stress signaling, 192–194  
 pathology and  
   cognition, 298  
   neuronal survival response, 139–140  
 pathophysiology  
    $\beta$ -amyloid role in, 439–443  
   and BDNF down-regulation, 280  
 pharmacogenetics, 361–363  
 plasma triglyceride levels and GOT, GPT, and GGT in, 360  
 protein misfolding manifestations, 123–129  
 redox proteomics identification of oxidatively modified brain proteins, 154–160  
 AD models for A $\beta$ (1-42), 159–160  
 cholinergic dysfunction, 157–158  
 CO<sub>2</sub> transport, 159  
 energy dysfunction, 156–157  
 excitotoxicity, 157  
 lipid abnormalities, 157–158  
 LTP, 158–159  
 neuritic abnormalities, 158  
 pH buffering, 159  
 proteasomal dysfunction, 157  
 synaptic abnormalities, 158–159  
 tau hyperphosphorylation, 158  
 stem cell therapy in, 255–262  
 tau in, 171–173  
 tauopathies and, 124–126  
 two-dimensional maps of brain proteins, 151–152  
 two-hit hypothesis, 195–198  
 vascular risk factors in, 206–208  
 Alzheimer's disease brain  
   acetylcholinesterase expression in, 429–435  
   ACh receptors in, 404  
   glutamatergic dystrophic neurites in, 397–398  
 Alzheimer's disease mouse model, A $\beta$  vaccine and AAV in, 265–271  
 Alzheimer's Disease Neuroimaging Initiative (ADNI), 183–189  
 Clinical Coordination Center, 186–187

- Clinical Core, 187–188
- Neuroimaging Core, 187–188
- objectives, 184
- structural organization, 185–186
- Amantadine sulfate, 33
- Ambenonium, 441
- $\gamma$ -Aminobutyric acid (GABA), 38, 61, 465, 468–470
- $\alpha$ -Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)
  - receptors, 157
- Aminoisopropylpropionic acid (AMPA)
  - receptors, 407
- Amnesia, 2
- Amplex-Red cholesterol assay, 225
- $\beta$ -Amyloid ( $\beta$ A), 113–119, 123–124, 126, 133, 136–137, 139–142, 154–155, 161, 171–173, 231, 237–239, 265, 291, 298
  - deposition and neuroinflammatory response in AD, 114–115
  - production and cholesterol, 221–228
  - sGAGs interactions with, 233–235, 247–248
- Amyloid- $\beta$ -peptide, *see* B-Amyloid protein
- Amyloid- $\beta$  protein precursor (A $\beta$ PP) gene, 113–116, 123–124, 128, 135, 137, 139, 154, 194, 197–198, 221–223, 228, 231, 238, 265, 298–300, 305, 337, 355–356, 369–370, 390, 439–442, 445–446
  - AChE effect on expression and metabolism of, 441–442
  - function in stem cell biology, 259–262
  - nonamyloidogenic metabolism of, 440–442
  - phenserine and cymserine effect on, 450–451, 456–458
  - physiological processing, 305–312
    - ADAM9 and, 305, 311–312
    - ADAM10 and, 305, 309–313, 394
    - ADAM17 and, 305, 309–310
    - up-regulation by PKC agonists, 307–309
  - $\alpha$ -secretase processing, 305–308
- $\beta$ -Amyloid derived diffusible ligands (ADDLs), 382
- Amyloid oligomer disease pathogenesis, cellular membranes as targets in, 381–384
- Amyloid pathology
  - dystrophic neurites generation, 396–398
  - neurotransmitter-specific progression of, 393–398
  - structural vulnerabilities to extracellular A $\beta$  burden, 393–396
- $\beta$ -Amyloid peptide, *see* B-Amyloid protein
- Amyloid plaques
  - targeting with phage anti-A $\beta$ P ScFv, 275–277
  - in vivo* targeting of, 274
- $\beta$ -Amyloid precursor protein ( $\beta$ APP), *see* Amyloid- $\beta$  protein precursor (A $\beta$ PP) gene
- $\beta$ -Amyloid protein, 293, 305, 318, 325, 334, 337, 369, 375, 382–383, 394, 411, 418, 439, 445, 451–452, 456–458
  - immunization with phage-ScFv against, 274–275
  - phenserine and cymserine effect on, 445–458
- Amyotrophic lateral sclerosis (ALS), 81, 231, 298
- Amyotrophy, 81, 85–86, 128
- Anarthria, 32
- Annonacine models of PD, 117
- Anti- $\beta$ -amyloid antibodies, intranasal administration, 273–277
- Antithrombotic prophylaxis, 32
- Anxiety, 3
- A30P  $\alpha$ -synuclein mice, 160–161
  - antibodies and immunohistochemistry, 99
  - brain tissue extraction, 100
  - carbonyl detection, 101
  - DJ-1 co-immunoprecipitates with tau and phospho-tau in brain homogenates, 105–106
  - DJ-1 expression in, 97–109
  - DJ-1 levels, 102–103
  - DJ-1 presence in reactive astrocytes in brain sections from Contursi kindred, 103–105
  - DJ-1 siRNA
    - knockdown confers susceptibility to oxidative insult in cell culture, 106–107
    - transfection, 101–102
  - immunoblot analysis, 100
  - immunoprecipitation, 101
  - LDH assay, 102
  - oxidative stress response, 103, 108
  - quantification of immunoblots, 100
- Apathy, 2–3
- Aphagia, 32

- APLP-1 proteins, 260  
 APLP-2 proteins, 260  
 ApoE-ApoE receptor, 212  
 Apolipoprotein E3 (ApoE3), 343, 355–356  
   alleles, 213, 217  
   deficient mice, 344–351  
     F4/80-positive microglia, 345, 348–351  
     IL-1 $\beta$ -positive cells, 345–348, 351  
     immunohistochemistry, 345  
     intracerebroventricular injection of LPS, 344  
     mac-2-positive microglia, 345, 348–351  
     NF- $\kappa$ B-positive cells, 345–348, 350–351  
   knock-in mice, 387, 390  
 Apolipoprotein E4 (ApoE4)  
   alleles, 135, 137, 213–214, 217, 298  
   brain inflammation in AD patients, 343  
   isoform-specific effects on brain inflammation, 343, 345  
   knock-in mice, 387, 390–391  
   NF- $\kappa$ B signaling activation by, 343–351  
   transgenic mice, 344–351  
     F4/80-positive microglia, 345, 348–351  
     IL-1 $\beta$ -positive cells, 345–348, 351  
     immunohistochemistry, 345  
     intracerebroventricular injection of LPS, 344  
     mac-2-positive microglia, 345, 348–351  
     NF- $\kappa$ B-positive cells, 345–348, 350–351  
 Apolipoprotein E2 (ApoE2) alleles, 213, 217  
 Apolipoprotein E (ApoE) gene, 172, 191, 206, 208, 211, 213–216, 221  
   CYP2D6 polymorphisms association with, 365  
   functional genomics studies, 356  
   interactions with liver function and drug metabolism, 361  
   pharmacogenetics, 361–363  
   pleiotropic effects in dementia, 356–361  
   related  
     aortic atherosclerosis, 359  
     cholesterol levels in AD, 357–358  
     GOT, GPT and GGT activity in AD, 359  
     lipid metabolism and atherosclerosis, 361  
     plasma triglyceride levels in AD, 357–358  
   Apomorphine, 32–33  
   Apoptosis, 133–134, 247  
   Apoptosis associated with neurodegeneration  
     glycosaminoglycans role, 249–253  
       animals for, 249  
       drugs and chemicals, 249–250  
       immunohistochemistry, 250–251  
       tissue preparation for histochemical assays, 250  
   APP CT100 transgenic mice, 430–431  
   *APP* genes, 114, 171  
   APP<sub>K670N, M671L</sub> + PS1<sub>M146L</sub> transgenic mutant mouse models, 394–396  
   APP<sub>K670N, M671L</sub> (tg2576) transgenic mutant mouse models, 394  
   APP<sub>K670N, M671L</sub> 03 transgenic mutant mouse models, 394  
   APP (SW) Tg2576 transgenic mice, 431  
   Arctic-type A $\beta$ , 390  
   Argyrophilic grain disease (AGD), 375–379  
     frequency in AD, 377–379  
     immunohistochemistry, 376–377  
     relation with 4R tau score in AD, 378  
   Argyrophilic grains (AGs), 375  
   Arylesterase, 362  
   A53T  $\alpha$ -synuclein mutation, 98, 104  
   Ateroid, therapeutic effect, 240  
   ATP synthase- $\alpha$ , 156  
   Atropine, 440–441  
   Autologous tissues, 51  
   Autophagy, 334  
   Autosomal recessive juvenile parkinsonism (ARJP), 127  
   BACE I, 221, 223  
   Base excision repair (BER), 17  
   Basic fibroblast growth factor (bFGF), 53–54  
   Basque families with LRRK2 gene, clinical and pathological description of, 84  
   Bcl-2 gene, 320  
   BDNF mRNA, 280–281  
   Behavioral-occupational therapy, 24  
   Behavioral problems, 11  
   BE-M17 cells, 101–102  
   Biochemical for PD detection, 41–42  
   Bioluminescence imaging technique, 175  
   Bioluminescent imaging  
     of brain injury in SBE-luc reporter mice, 179–181  
     excitotoxic and endotoxic brain injury in mice, 175–181

- method, 176–177
  - models, 176
  - results and discussion, 177–181
  - stereotactic injections, 176–177
  - tissue preparation, 177
- Biomarkers**
- for AD, 169–173
  - in body fluids of PD patients, 173
  - CSF for AD, 172
  - definitions, 170–171
  - for PD detection, 35–43, 169–171
    - biochemical markers, 41–42
    - definitions, 39
    - functional imaging, 40
    - gene expression in blood, 43
    - genetic markers, 42–43
    - neuromelanin blood test, 42
    - tests on olfaction, 41
    - tests on vision, 41
    - transcranial ultrasonography, 40
    - translation of pathological findings, 37–39
  - qualities, 169–170
  - uses of, 169–170
- Bipolar disorder, 317**
- Blessed Dementia Scale score, 173**
- Blood-brain barrier (BBB) in PD, 36–37,**  
59–60, 240, 273, 275, 277, 371
- $\alpha$ 3 $\beta$ 4 nAChRs receptors, 464, 466–467
- $\alpha$ 4 $\beta$ 2 nAChRs receptors, 466–468, 469–470
- Body mass index (BMI), 207**
- Bone fracture, 32**
- Bone morphogenetic proteins (BMPs), 175**
- Boundary shift integral (BSI) methods, 187**
- Braak stages in PD, 39**
- Brachydactyly, 13**
- Bradykinesia, 23, 26, 76, 78–79, 82, 85, 159**
- Brain**
- cholesterol homeostasis in, 211–213, 217
  - inflammation in ApoE4 AD patients, 343
- Brain-derived neurotrophic factor (BDNF)**
- cells, 93–94, 196, 258, 291–292, 294
  - in AD, 279–281
- Brief Smell Identification Test (B-SIT), 41**
- Bromocriptine, 33**
- Bronchopneumonia, 32**
- Butyrylcholinesterase (BuChE), 362, 405,**  
449, 452–457
- Calpains, 309, 334**
- Campbell-Switzer silver stain, 414, 418**
- Carbidopa therapy, 76, 78–80, 82–85**
- $\beta$ -Carbolines, 36**
- Carbonic anhydrase II (CA-II), 156, 159–161**
- Cardiac arrhythmias, 32**
- Cardinal motor symptoms, 36**
- Cardiovascular Risk Factors, Aging,**  
and **Dementia (CAIDE) study,**  
205–209
- Caspase-3 activation, 247**
- Caspase-3 enzyme, 134**
- Caspase-3 immunoreactivity,**  
intracerebroventricular AF64A  
administration effect on, 251–252
- Catalase, 193, 362**
- Catechins gallate esters, 293**
- Catechol-O-methyltransferase (COMT), 362**
- Cathepsin B, 309**
- CD4 cells, 53**
- CD8 cells, 53**
- CDCrel-1 protein, 11**
- CDNA microarray technology, 19**
- CDR power of attention tests, 5**
- CD4+ T cells, 268**
- CD8+ T cells, 268**
- Cell line grafting for PD treatment,**  
51–55
- and encapsulation, 52
  - intracerebral, 54
  - neurotransmitter and neurotrophic  
factor secretion control after,  
54–55
  - neurotransmitter-secreting, 52–53
  - neurotrophic factor-secreting, 53
  - simultaneous delivery of  
neurotransmitter and  
neurotrophic factor, 53–54
- Cellular prion protein (PrP<sup>c</sup>), 305**
- Central nervous system (CNS), 211, 217, 285,**  
319, 405, 413, 416, 463
- apolipoprotein E and cholesterol  
transport in, 213–214
  - selective nAChRs potentiators, 466–468
- Cerebellar ataxia, 11**
- Cerebellar dysfunction, 76**
- Cerebral amyloid angiopathy (CAA), 390**
- Cerebral infarcts, 135, 137**
- Cerebro spinal fluid (CSF), 171–172, 213,**  
222, 273–274, 298, 395, 413,  
416, 431
- ChAT immunoreactivity, 249, 251**  
intracerebroventricular AF64A  
administration effect on, 252–253
- ChEI tacrine (9-amino-1,2,3,**  
4-tetrahydroacridine  
hydrochloride), 458

- Cholesterol  
 biosynthetic pathway, 224  
 A $\beta$  production, 221–228  
 de novo synthesis assay, 223–226  
 homeostasis  
   in brain, 211–213, 217  
   and cholesterol-lowering drugs,  
     214–217, 222  
 identifying target enzyme, 226–227  
 lowering drugs, 214–217  
 synthesis in eukaryotic cells, 212  
 transport and production in AD, 211–217
- Choline acetyltransferase (ChAT)  
 enzyme, 286, 403–404, 415–416, 432–434  
 immunohistochemistry, 249  
*See also* ChAT immunoreactivity
- Cholinergic-amyloid fusion hypothesis, for  
 A $\beta$  deposition, 411–421
- Cholinergic basal forebrain (CBF) neurons,  
 285–286
- Cholinergic changes in AD, 393–394,  
 403–405, 407
- Cholinergic neurites, in AD plaques, 432
- Cholinergic neurons  
 deficits, 4, 6  
 role in synaptic scaling, 433–434
- Cholinergic therapy  
 of immunotoxin-lesioned animals, 415,  
 419–420  
 of normal animals, 413, 416
- Cholinesterase inhibition,  $\beta$ -amyloid role in,  
 439–443
- Cholinesterase inhibitors (ChEIs), 4, 6,  
 445–447, 454
- Chorea, 76
- Chromaffin cells, 51, 55
- Ciliary neurotrophic factor (CNTF), 53, 55
- C-Jun N-terminal kinase (JNK), 142, 295
- Clioquinol, 454
- 4396C monoclonal antibody, 388
- Cognitive decline, decreased ProBDNF as  
 cause of, 279–281
- Cognitive impairment symptoms, 23
- Cogwheel rigidity, 159
- Conformational disease, 381
- Continuous administration of MPTP model  
 of PD, 62–63
- Coomassie Blue staining, 151
- Cortical cholinergic lesion, causes of A $\beta$   
 deposition, 411–421
- Corticobasal degeneration (CBD), 40, 231
- COS-7 cells, 226–227, 311
- Creatine kinase BB (CK), 156
- Creutzfeldt-Jakob disease (CJD), 172, 231, 307
- CSF biomarkers, 172
- C3435T polymorphism, 36
- Cultured hippocampal neurons, patch-  
 clamp recordings in, 465–466
- Curcumin, 454
- Cu/Zn superoxide dismutase, 193
- $\alpha$ -Cyano-4-hydroxycinnamic acid, 153
- Cyclooxygenase-2 (COX-2) protein  
 expression, 20
- Cymserine, 446–447  
 analogs, 446  
 assessed at nontoxic doses in SK-N-SH  
 cells, 449–450  
 differential effects on  
   soluble A $\beta$ , 451–452, 456–458  
   soluble APP levels, 450–451, 456–458  
 effect on  
   amyloid pathway, 454  
   cell viability, 450  
   cholinesterase inhibition, 452  
   human AChE and BuChE inhibition,  
     452, 455–458  
   lipophilicity of, 453–454, 457  
   pharmacologic properties, 453–454
- CYP1A1, 362
- CYP1A2, 362–363
- CYP2A6, 362
- CYP3A4, 362–363
- CYP3A5, 362
- CYP3A7, 362
- CYP1B1, 362
- CYP2B6, 362
- CYP2C8, 362
- CYP2C9, 362
- CYP2C19, 362
- CYP2D6, 362–365  
 ApoE genotypes association with, 365  
 genotypes in AD, 364  
 polymorphisms in AD, 363–364
- CYP2E1, 362
- Cysteine-rich extracellular domain  
 (CRD), 319
- Cytochrome P450 enzymes, 362
- Cytokines, from activated microglia  
 in putamen in PD, 92
- Cytokines gene expression in PD, 91–95  
 in hippocampus and putamen, 93–94
- Dantrolene, 33
- Dardarin* gene, 13
- Dardarin* R1396G mutation, 84
- Deep brain stimulation surgery, 51

- Delusions, 3
- Dementia, 11, 76, 85–86, 128
  - ApoE pleiotropic effects in, 355–365
  - associated with PD
    - behavioral features, 3
    - clinical features, 1–3
    - cognitive features, 2–3
    - treatment, 3–6
- Dementia with Lewy bodies (DLB), 2, 9, 34, 40, 91, 126, 232
  - cortical AChE and midfrontal ChAT activity, 4
- Dementiform cognitive impairments, 38
- Depression, 3, 172
- Detergent-resistant microdomains (DRMs), 390–391
- Developmental processes, Wnt signaling in, 317
- Diabetes mellitus, 135, 137
- 3,4-Diaminopyridine, 441
- Dihydropyrimidinase-related protein 2 (DRP2), 156, 158
- Dihydropyrimidine dehydrogenase (DPD), 362
- 2,5-Dihydroxybenzoic acid, 153
- 2,4-Dinitrophenylhydrazine (DNPH), 149, 151
- Disinhibition, 3
- Disseminated intravascular coagulation, 32
- Distal limb muscle weakness, 81
- DJ-1-deficient mice, 65
- DJ-1* gene, 13, 15, 76, 97–98, 127, 159, 161
  - expression in A30P  $\alpha$ -synuclein mice, 97–109
  - mutations in, 171
- D-KEFS Test Battery, 5
- DNA repair systems
  - base excision repair (BER), 17
  - mismatch repair system (MMR), 17–18
  - mitochondrial dysfunction and excitotoxicity sensitivity, 17–20
  - nucleotide excision repair (NER), 17
- Donepezil, 4, 405, 439–442
- Dopa/dopaminequinone, 11
- Dopamine  $\beta$ -hydroxylase (DBH), 414
- Dopamine (DA), 10, 33, 36–37, 40, 51–55, 91, 173
  - $\alpha$ -hydroxylase immunostaining, 57
  - inhibition of UP system in PC12 cells, 67
  - metabolism, 57, 67
  - producing cells, 51–52
  - secreting cell line, 52, 54
  - secretion from grafted PC12 cells, 52–54
  - secretion from PC12th Tet-Off cells, 54–55
- Dopaminergic nigrostriatal system, 37
- Dopaminergic system, 38, 54
- Dopaminomimetic therapy, 76, 83
- Dorsal glossopharyngeus-vagus complex, 117
- Down's syndrome (DS), 136, 140, 142, 158, 192, 194, 300
- Downstream signaling systems,  $\alpha$ -secretase pathway up-regulation, 370–371
- Doxycycline, 55
- Drosophila*, 319, 433
- Drosophila melanogaster*, 58
- DSM-IV criteria, 4, 206
- Dual task effect, 26–27
- Duodenal ulcer, 32
- Dutch-type A $\beta$ , 390
- Dysautonomia, 31, 76
- Dysexecutive syndrome, 2
- Dyskinesia, 25, 78–80
- Dystonia (Meige syndrome), 76, 81, 85, 87
- EAAT2 (GLT-1), 157
- Eeserine, 446
- Electrospray ionization (ESI), 152–153
- Embryonic stem (ES) cells, 256
- Encapsulated cell line grafting, for neurological disorders, 52, 55
- $\alpha$ -Enolase, 156, 160
- Enzyme-linked immunosorbent assay (ELISA), 92, 172, 269, 288, 412, 415, 418, 447–448, 451–452, 456
- Epigallocatechin gallate (EGCG), 293–294
- Ethylcholine aziridinium (AF64A), 248–251
  - intracerebroventricular administration effect on
    - caspase-3 immunoreactivity, 251–252
    - ChAT immunoreactivity, 252–253
- Eukaryotic cells, 17, 212
- Excitatory neurotransmitter systems, 38
- Excitotoxic and endotoxic brain injury in mice
  - bioluminescent imaging, 175–181
  - models, 176
  - stereotactic injections, 176–177
  - tissue preparation, 177
- Excitotoxicity sensitivity and impaired DNA repair systems, 17–20
- Executive functions, abnormalities in, 2
- Faber disease, 227
- Fabry disease, 227
- Familial AD (FAD), 124, 197–198, 221, 298
- Familial PD, 9–15, 35, 43, 76, 97, 127

- Family A (German-Canadian) with LRRK2 gene  
 clinical and pathological description of, 79–81  
 neuropathology of, 81  
 pedigree of, 80  
 PET studies, 82
- Family D (Western Nebraska) with LRRK2 gene  
 clinical and pathological description of, 75–79  
 pedigree of, 77  
 PET studies, 82
- Family 469 with LRRK2 gene, clinical and pathological description of, 82
- Fasciculations, 81
- Fatal familial insomnia, 231
- Fetal nigral cells, 51
- FINMONICA study, 206
- Flemish-type A $\beta$ , 390
- Flu, 32
- Fluorescent imaging plate reader (FLIPR), 464–465
- Flurbiprofen, 124
- FOXO3a, IGF-1 effect involving PI3/AKT pathway and, 292
- Frizzled genes, 319–320  
 expression in rat neuronal cells, 317–322  
 present in proximal TCF/LEF binding sites, 320
- Frontotemporal dementia (FTDP-17), 325, 337–338
- Frontotemporal dementias (FTDs), 123, 235  
 CSF biomarkers for, 172  
 protein misfolding manifestations, 123–129  
 tau mutations in, 326, 333
- Functional imaging, and biomarkers for PD detection, 40
- GA $\beta$   
 determinant for area-specific deposition of A $\beta$ , 390–391  
 generation in brain, 389–390  
 immunohistochemistry and immunoprecipitation of, 389  
 immunological detection in brain, 388–389  
 monoclonal antibody specific to, 388  
 as seed for Alzheimer amyloid, 388–391
- Gait disturbances symptoms, 23
- Gait hypokinesia, 25
- Galantamine, 4, 405, 439–443
- Galanthamine, 464
- Ganglioside, 222–223
- Ganstigmine, 440–442
- Gastric stasis, 32
- Gaucher's disease, 128, 227
- Gene expression, in blood for PD detection, 43
- Genetic markers, for PD detection, 42–43
- Genetic models, of PD, 63–67
- Gerstmann-Straussler-Scheinker disease, 232
- Ginkgo biloba, 454
- Glial cell line-derived neurotrophic factor (GDNF), 24, 53–54
- Glial cells, 233
- Glial fibrillary acidic protein (GFAP), 406
- Glial glutamate transporter (GLT-1), 406
- Global Cognitive Score (GCS), 281
- Glucocerebrosidase gene (GBA), 128
- Glucose-6-phosphate dehydrogenase, 362
- Glucosyltransferase, 362
- Glu46Lys mutation, 10
- Glutamate oxaloacetate transaminase (GOT), 359–361
- Glutamate-pyruvate transaminase (GPT), 359–361
- Glutamatergic changes, in AD, 405–407
- Glutamatergic dystrophic neurites, in human AD brain, 397–398
- Glutamatergic transmission, 38
- Glutamate transporter (GLT-1), 155
- Glutamine synthase (GS), 156–157
- $\gamma$ -Glutamyl transaminase (GGT), 359–361
- Glutathione-S-transferase (GST), 155, 310, 362
- Glutathione-S-transferases A (GST-A), 362
- Glutathione-S-transferases M (GST-M), 362
- Glutathione-S-transferases P (GST-P), 362
- Glutathione-S-transferases T (GST-T), 362
- Glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ), 318, 337–338
- Glycogen synthase kinase-3 (GSK-3), 126, 140, 337–338
- Glycosaminoglycans (GAGs)  
 and analogs in neurodegenerative disorders, 231–241  
 mimetics, 124  
 neuroprotective role of, 247–248  
 role in apoptosis associated with neurodegeneration, 249–253  
 synthesis and physiological functions, 232–233

- therapeutic implications, 237–241  
*See also* Sulfated glycosaminoglycans (sGAGs)
- Glycosylated alpha-synuclein, 11
- GM1-bound A $\beta$  (GA $\beta$ ), *see* GA $\beta$
- GM1 ganglioside (GM1), 387–391
- GM1-gangliosidosis, 227
- GM2-gangliosidosis, 227
- G protein-coupled receptors activation, for  $\alpha$ -secretase pathway up-regulation, 370–371
- Gracile axonal dystrophy (*gad*), 12
- G2019S families with LRRK2 gene, clinical and pathological description of, 83–84
- GSHPx, 193
- GSSG-R, 193
- Gut immune system, 269–270
- Hallervorden-Spatz disease, 38
- Hallucinations, 3, 38
- HEK293 cells, 266–267, 311, 318, 371
- Hematoxylin and eosin (H&E) staining, 267
- Heme oxygenase-1, 193
- Hemiparkinsonism-hemiatrophy, 11
- Heparan sulfate proteoglycan (HSPG), 414–415
- Heparin, 239, 241
- HepG2 cells, 371
- Heptylphysostigmine, 441
- Hereditary nonpolyposis colorectal cancer (HNPCC), 17
- Hexahydropyrroloindole, 446
- High density lipoprotein (HDL), 213, 217
- Hippocampal cells, 318
- Hippocampal neurons, tea extracts protection of, 293
- Histamine methyltransferase (HMT), 362
- HIV-1 Nef gene, 94
- Hoehn and Yahr scale, 36
- HtrA2/Omi* gene, 11–12
- Human ADAM10 promoter, and  $\alpha$ -secretase pathway up-regulation, 371–373
- Human amniotic epithelial cell, 54
- Human ApoE3 transgenic mice, 344–351  
 F4/80-positive microglia, 345, 348–351  
 IL-1 $\beta$ -positive cells, 345–348, 351  
 immunohistochemistry, 345  
 intracerebroventricular injection of LPS, 344  
 mac-2-positive microglia, 345, 348–351  
 NF- $\kappa$ B-positive cells, 345–348, 350–351
- Human cerebrovascular smooth muscle cells (HCMSs), 390
- Human CNTF protein, 55
- Human-derived cell line, intracerebral grafting for PD, 54
- Human embryonic kidney (HEK) cells, 266
- Human Frizzled genes, TCF/LEF boxes found in, 320
- Human leukocyte antigen-DR (HLA-DR), 91
- Human MeSCs (HMeSCs), 256–262
- Human neuroblastoma (SK-N-SH) cells, 61, 448  
 APP measurement, 448  
 A $\beta$  assay, 448  
 cell culture, 448  
 cholinesterase measurements, 449  
 LDH and MTT assays, 448  
 lipophilicity determination, 447–448  
 phenserine, cymserine, and physostigmine assessed at nontoxic doses in, 449–450  
 differential effects on soluble A $\beta$ , 451–452, 456–458  
 differential effects on soluble APP levels, 450–451, 456–458  
 effect on cell viability, 450  
 effect on cholinesterase inhibition, 452  
 effect on human AChE and BuChE inhibition, 452, 455–458  
 lipophilicity of, 453–454, 457  
 pharmacologic properties, 453–454
- Human SH-SY5Y neuroblastoma cells, 18
- Huntington's disease, 55, 139, 381–382
- 8-Hydroxy-2'-deoxyguanosine, 41
- 6-Hydroxydopamine (6-OHDA), 53, 58–59, 91  
 model of PD, 24, 58–59, 62
- 8-Hydroxyguanosine (8OHG), 41, 194
- 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, 212, 214–216, 222–223, 226
- 3-Hydroxy-3-methylglutaryl reductase (HMGR), 211–212, 214, 216, 223, 226
- 4-Hydroxy-2-trans-nonenal (HNE), 149, 151, 155, 158
- Hypercholesterolemia, 135, 137, 221–222
- Hyperhomocysteinemia, 135, 137
- Hyperhydrosis, 11
- Hyperreflexia, 85–86
- Hyperthermia, 31–32, 34
- Hyposmia, 41

- Ideomotor apraxia, 3  
 Idiopathic Parkinson's syndrome (IPS), 35  
 $\beta$ III-tubulin, 257, 259, 261  
 Ile93Met mutation, 65  
 Immunoprecipitation, 150  
 Immunotoxin lesion of nbm, 413–419  
 Impaired attention, 2  
 Impotence, 11  
 Inducible nitric oxide synthase (iNOS), 149  
 Insertion/deletion loops (IDLs), 17  
 Institutional Animal Care and Use Committee (IACUC), 176  
 Insulin-like trophic factor-1 (IGF-1), 291  
   neuroprotective effects of, 292  
   PI3/Akt pathway and FOXO3a, 292  
 Interleukin-6 (IL-6), 92–94  
 Intracerebral cell grafting, 51  
   of cell lines, 53  
   of human-derived cell line, for PD, 54  
 Intracerebroventricular AF64A  
   administration effect on  
     caspase-3 immunoreactivity, 251–252  
     ChAT immunoreactivity, 252–253  
 Intraneuronal A $\beta$  and AD, 297–301  
*In Vivo* Imaging System, 177  
 Iron-regulatory protein (IRP), 458  
 Irritability, 3  
 Islet amyloid polypeptide (IAPP), 383  
 Isoelectric focusing (IEF), 151
- Jejunal volvulus, 32
- Kainic acid (KA), 18, 20  
   excitotoxin, 176, 179–180  
   induced brain injury bioluminescent imaging, 179–180
- Ki-M1p-positive resting microglia, 92  
 Krabbe disease, 227  
 Kufor-Rakeb syndrome, 14  
 Kuopio MCI study, 206  
 Kuru, 231  
 KXGS motifs, 333
- Lactate dehydrogenase (LDH), 448–450, 456  
 Language deficits, 2–3  
 Laryngitis, 32  
 L-dopa-responsive parkinsonism, 9–10, 12, 14  
 Leucine-rich repeat kinase 2 (LRRK2) gene,  
   *see* *LRRK2* genes  
 Leukocyte function associated antigen-I  
   (LFA-I), 92  
 Leu17 peptidyl bond, 310–311  
 Levodopa therapy, 76, 78–80, 82–85
- Lewy bodies disease (LBD), 40–41, 67, 91,  
   117, 127  
   CSF biomarkers for, 172  
   cytokines gene expression in  
     hippocampus and putamen,  
     93–94  
   neuroprotective and neurotoxic subtypes  
     of activated microglia in, 94  
 Lewy bodies (LBs), 9–10, 23, 34, 36, 38, 58,  
   60, 63–64, 66, 68, 78, 81, 91, 97,  
   107, 117, 123–124, 126–128, 133,  
   138–140, 232, 237  
 Lifestyle-related factors and AD, 208  
 Lipids and AD, 222–223  
 Lipophilicity determination, 447–448  
 Lipopolysaccharide (LPS) endotoxin, 176,  
   179–180  
 Lipopolysaccharide models, of PD, 117  
 LivingImage software (Xenogen), 177  
 Low density lipoprotein (LDL), 212,  
   215–217  
 LRP5 proteins, 319  
 LRP6 proteins, 319  
*LRRK2* genes, 13–15, 127–128  
   Basque families and British Kindred, 84  
   clinical and pathological  
     characterization, 75–88  
   family 469, 82, 86  
   family A (German-Canadian), 79–81, 86  
   family D (western Nebraska), 75–79, 86  
   G2019S families, 83–84  
   mutations in, 171  
   PET studies, 82  
   and ROCO gene, 82–83  
   Sagamihara family, 75, 84–86  
 Lrrk2 protein, 82–83, 85  
 Lymphoid enhancer-binding factor (LEF), 318  
 Lysine 63-linked ubiquitylation, 11  
 Lys16 peptidyl bond, 310–311
- Major histocompatibility complex (MHC),  
   91–93  
 Malignant syndrome (MS), 31–33  
 MAPKKK (mitogen-induced protein kinase  
   kinase kinase), 14  
 MAPT gene, 333, 355–356  
 Matrix-assisted laser desorption/ionization  
   (MALDI), 152–153  
 MDR1 gene, 36–37  
 Median forebrain bundle (MFB), 58–59  
 Memory functions, in PDD, 2  
 Memory impairment, 2  
 Mendelian, 355

- Meningoencephalitis, 268–269
- Mental status, alterations of, 31
- Meperidine, 59
- Mesenchymal stem cells (MeSCs), 256–258
- Metachromatic leukodystrophy, 227
- Methamphetamine (MA), 58
- 3,4-Methylenedioxymethamphetamine (MDMA), 58
- 1-Methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), 60
- 1-Methyl-4-phenylpyridinium (MPP+), 60
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
- intoxication, 36, 52, 58, 63, 91, 97, 108, 117, 161
  - models of PD, 59–60, 62
- Metrifonate, 439–442
- Michael addition reaction, 149
- Microglia in PD, *see* Activated microglia in PD
- Mild cognitive impairment (MCI), 136, 172, 184, 194–195, 205–209, 285, 287, 297, 372, 394, 432
- in AD, 281, 285
    - basocortical cholinergic markers in, 286
    - cholinergic alterations in, 286
    - NGF receptor levels in, 286–287
    - pro-NGF increases in, 287–288
    - vascular risk factors in, 206–208
- Mini-Mental Status Examination (MMSE), 5, 281, 289
- Mismatch repair system (MMR), 17–18
- Mitochondrial dysfunction, and impaired DNA repair systems, 17–20
- Mitogen-activated protein kinase (MAPK) pathway, 294
- Mitogen-activated protein (MAP) kinase, 442
- Monoamine oxidase B (MAO-B), 41, 362
- Morris-Water-Maze test, 370
- Mouse embryonic fibroblast (MEF) cell, 223
- Movement, slowness of, 25
- MPTP models of PD, 59–60, 62
- Msh2* gene, 18–19
- Msh2*<sup>+/-</sup> mice, 18–20
- MSH2-MSH6 (MutS $\alpha$ ), 17
- MSH2-MSH3 (MutS $\beta$ ), 17
- Msh2*-null mice, 18
- MTT [3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide], 448, 450
- Multidrug resistant protein-1 (MRP-1), 155
- Multiple sulfatase deficiency, 227
- Multiple system atrophy (MSA), 3, 40
- Muscle atrophy, 81
- Muscle enzymes, incremental increases of, 31
- MutL and Muts homologs, 17
- N2a cell lines, 325–328, 330–333
- N-acetyltransferase, 362
- N-acetyltransferase 1 (NAT1), 362
- N-acetyltransferase 2 (NAT2), 362
- $\alpha$ -7 nAChRs receptors, 466–470
- NADPH oxidase expression, 94, 362
- NADPH-quinone oxidoreductase (NQO1), 362
- N2a/Tet-On/K18- $\rho$ K280 cell line, 327
- N2a/Tet-On/K18- $\rho$ K280/2P cell line, 327
- N2a/Tet-On/ K18-WT cell line, 327
- N2a/Tet-On/pBI-5 (mock) cell line, 327
- Natural products, neuroprotective effects of, 291–295
- Necrosis, 133
- Nerve growth factor (NGF), 53, 197, 248, 285–286, 288–289
- N-ethylmaleimide-sensitive factor (NSF), 158
- Neural stem cells (NSCs), 255–256, 260–262
- Neuroblastoma cells, 68
- Neurodegeneration
- mechanisms of, 149–162
  - oxidative insults and cell cycle reentry at, 135–139
  - and tau polymerization, 337–340
- Neurodegeneration with brain iron accumulation (NBIA), 38
- Neurodegenerative disorders
- glycosaminoglycans and analogs in, 231–241
- Neurofibrillary tangles (NFTs), 123, 133, 138–140, 154, 231, 233, 235, 237–238, 240, 298, 337, 356, 375–376, 411, 429
- Neuroleptic malignant-like syndrome (NMLS), 31–33
- Neuroleptic malignant syndrome (NMS), 31, 33–34
- Neurological disorders
- cell line grafting for, 55
  - encapsulated cell line grafting for, 55
- Neuromelanin blood test, for PD
- detection, 42
- Neuronal nicotinic acetylcholine receptors, 431–432
- $\alpha$ -7 Neuronal nicotinic acetylcholine receptors, 431–432, 434

- Neuronal nicotinic cholinergic receptors, allosteric potentiators of, 463–471
- Neuropil threads (NTs), 375, 377
- Neuropolypeptide h3, 156–157
- Neuropsychiatric Inventory (NPI), 5
- Neurotoxins, 36
- Neurotransmitter  
control after grafting into brain, 54–55  
delivery by cell line grafting for PD, 53–54  
secreting cell line grafting for PD, 52–53  
specific progression of amyloid pathology, 393–398
- Neurotrophic factor  
control after grafting into brain, 54–55  
delivery by cell line grafting for PD, 53–54  
secreting cell line grafting for PD, 53
- NF- $\kappa$ B signaling, 294  
enhanced activation by apolipoprotein E4, 343–351
- Nicotinic acetylcholine receptors (nAChRs), 463–464  
CNS selective potentiators, 466–468  
selective  $\alpha$ -7 potentiators, 468–470
- Niemann-Pick disease, 227
- Nigrostriatal dopaminergic system, 51
- NINCDS-ADRDA criteria, 206
- 3-Nitrotyrosine (3-NT), 149–151
- N-methyl-D-aspartate (NMDA) antagonist memantine, 157, 403, 405–407, 445, 454, 471
- No cognitive impairment (NCI), 285, 287
- Nonamyloidogenic metabolism of A $\beta$ PP, muscarinic cholinergic receptor stimulation effect on, 440–442
- Nonsteroidal antiinflammatory drugs (NSAIDs), 124, 136–137
- Noradrenergic locus coeruleus, 38
- Norepinephrine transporters (NET), 60
- North Karelia Project, 206
- Nucleotide excision repair (NER), 17
- Nucleus basalis magnocellularis, immunotoxin lesion of, 413–419
- Nucleus basalis (NB), 285–286
- Nucleus basalis of Meynert (nbM), cholinergic neurons deficits in, 4
- 8-OH-2 $\alpha$ -deoxyguanosine, 150
- Olfaction, tests for PD detection, 41
- Olfactory dysfunction, 41
- Oligomers, 382
- Omi* gene, 11–12
- Oncogenic processes, Wnt signaling in, 317
- Orthostatic hypotension, 11
- Oxidative insults and cell cycle reentry, at neurodegeneration, 135–139
- PACAP-induced activation, for  $\alpha$ -secretase pathway up-regulation, 371–342
- Paclitaxel, 126
- PAEL receptor protein, 11
- Paired helical filaments (PHFs), 233
- Paraoxonase, 362
- Paraquat, 36
- PARK2*, mutations in, 171
- PARK8*, 13–14, 75–88
- Parkin* gene, 10, 13, 15, 76, 88, 97, 109, 127, 137, 159  
models of PD, 64–65
- Parkin-knockout mouse model, 64
- Parkin protein, 10–11, 58
- Parkinsonian hyperpyrexia (PH), 31–32
- Parkinsonism-dementia complex of Guam, 231
- Parkinson's disease dementia (PDD), 126  
behavioral features, 3  
clinical features, 1–3  
cognitive features, 2–3  
treatment, 3–6
- Parkinson's disease (PD), 381–382  
activated microglia, 91–95  
neuroprotective and neurotoxic subtypes in brain, 94–95  
substantia nigra and putamen in brain, 92–93  
biochemical pathways mediated by genes implicated in, 97–109  
biomarkers for, 35–43, 169–173  
blood-brain barrier (BBB) in, 36–37  
Braak stages, 39  
causes, 35–36  
cell cycle reentry in, 138–139  
cell grafting for, 51–55  
cell replacement therapy for, 256  
characteristics, 35  
cognitive rehabilitation, 27  
cytokines gene expression in, 91–95  
hippocampus and putamen, 93–94  
definition, 23  
dementia associated with  
behavioral features, 3  
clinical features, 1–3  
cognitive features, 2–3  
treatment, 3–6  
*See also* Dementia

- diagnosis of, 36–37
- familial forms, 9–15, 43
  - PARK1, 9–10, 76
  - PARK2, 10–11, 76, 127
  - PARK3, 11–12, 76
  - PARK4, 12, 76
  - PARK5, 12, 76
  - PARK6, 12–13, 76, 127
  - PARK7, 13, 65, 76, 127
  - PARK8, 13–14, 75–88, 128
  - PARK9, 14, 76
  - PARK10, 14, 76
  - PARK11, 14, 76
- genes associated with, 63–67
- genetic causes, 36
- inflammation and pathological cascade in, 117–118
- models, 58–67
  - annonacine, 117
  - continuous administration of MPTP, 62–63
  - genetic models, 63–67
  - 6-Hydroxydopamine, 58–59, 62
  - ideal model, 58–59, 62
  - lipopolysaccharide, 117
  - MPTP, 59–60, 62, 117
  - parkin, 64–65
  - rotenone, 60–62, 117, 138
  - subcutaneous rotenone exposure, 62
  - $\alpha$ -synuclein, 66–67
  - Uch-L1, 65
  - in vivo environmental models, 62–63
- motor
  - impairment in, 25–26
  - rehabilitation for, 23–28
- neurochemical findings, 37–38
- neurogenetics in, 9–15
- neuroinflammation in early stages, 113–119
- neuronal
  - death in, 133–134
  - survival response, 139–140
- nosology of, 125, 128–129
- oxidative insult and neuronal survival role, 133–142
  - A $\beta$ , tau, and  $\alpha$ -synuclein function against, 140–142
  - genetic mutations and risk factors, 135–136
- oxidative stress, 41, 135–138
  - with genetic mutations and risk factors, 135–136
- paramedical therapies, 24
  - pathology, 38, 139–140
  - physical therapy in, 24–25
  - physiological strategies for motor problems in, 26
  - protein misfolding manifestations, 123–129
  - redox proteomics in, 159–161
  - synucleinopathies, 126–129
  - therapeutic target in, 68–69
- Patients with AD
  - acute akinesia in, 31–34
  - biomarkers in body fluids of, 173
  - cortical AChE activity, 4
  - memory impairment in, 2
  - midfrontal ChAT activity, 4
  - visuospatial function in, 2
  - See also* Alzheimer's disease (AD)
- PC12 cells, 52, 67–68
- PC12-GDNF cell line, 54
- PC12th Tet-Off cells, 54–55
- Peptide mass fingerprinting, search engines for, 153
- Peptidyl prolyl cis-trans isomerase (Pin 1), 156
- Peripheral nervous system (PNS), 214
- Peripheral neuropathy, 11
- Peroxioredoxins, 193
- P-glycoprotein (P-gp) protein, 36
- Phenserine, 441–442, 446–447
  - assessed at nontoxic doses in SK-N-SH cells, 449–450
  - differential effects on
    - soluble A $\beta$ , 451–452, 456–458
    - soluble APP levels, 450–451, 456–458
  - effect on
    - amyloid pathway, 454
    - cell viability, 450
    - cholinesterase inhibition, 452
    - human AChE and BuChE inhibition, 452, 455–458
    - lipophilicity of, 453–454, 457
    - pharmacologic properties, 453–454
- PHFtau proteins, 125
- Phosphatidylethanolamine-binding protein (PEBP), 157–158
- Phosphatidylinositol 3-kinase (PI3K), 291
- Phosphoglycerate mutase 1 (PGM1), 156
- Physiological processing of  $\beta$ -APP and TSEs, 305–312
  - ADAM9 and, 305, 311–312
  - ADAM10 and, 305, 309–313
  - ADAM17 and, 305, 309–310
  - up-regulation by PKC agonists, 307–309

- Physostigmine, 441, 446–447, 464  
   assessed at nontoxic doses in SK-N-SH cells, 449–450  
   differential effects on  
     soluble A $\beta$ , 451–452, 456–458  
     soluble APP levels, 450–451, 456–458  
   effect on  
     amyloid pathway, 454  
     cell viability, 450  
     cholinesterase inhibition, 452  
     human AChE and BuChE inhibition, 452, 455–458  
     lipophilicity of, 453–454, 457  
     pharmacologic properties, 453–454  
 Pick's disease, 98, 231  
*PINK1* (PTEN-induced kinase 1) gene, 12–13, 15, 76, 97, 127, 159, 161  
   mutations in, 171  
 Pituitary adenylate cyclase-activating polypeptides (PACAP), 371  
 Placebo, 4–6, 24, 34  
 Plasma membrane, as target in amyloid oligomer disease pathogenesis, 381–384  
 Plasmin, 309  
 PL kindred, British family, 84  
 P75 neurotrophin receptor (p75NTR), 285–289, 413  
 Positron emission tomography (PET), 36, 40  
 Postsynaptic density protein 95 (PSD-95), 321–322  
 Postural instability symptoms, 23  
 Postural reflexes, loss of, 23  
*Presenilin-1* (*PS-1*) gene, 114, 124, 135, 137, 139, 171, 198, 221–222, 298, 355–356  
*Presenilin-2* (*PS-2*) gene, 114, 124, 135, 137, 139, 171, 198, 221–222, 298, 355–356  
 Presynaptic cholinergic markers, 4  
 Prion disease, 113, 231, 238  
 Prion protein, interactions with sGAGs, 235–237  
 ProBDNF level, cause of cognitive decline and neurodegeneration, 279–281  
 Prodromal AD, TrkA/ProNGF balance in, 285–289  
 Progressive SPS, 41  
 Progressive supranuclear palsy (PSP), 3, 40, 231  
 ProNGF, 285–289  
 Proprioceptive neuromuscular facilitation techniques, 24  
 Prostate-specific antigen (PSA), 169  
 Proteasome gelatinase A, 309  
 Protein kinase A (PKA), 307–308, 371  
 Protein kinase C (PKC), 291, 305, 307, 309–310, 370–371, 442–443  
 Proteoglycan (PG), 232–233, 237  
 Proteomics, 150–151  
 Prototypical dementia syndrome associated with PD (PDD)  
   behavioral features, 3  
   clinical features, 2  
   cognitive features, 2–3  
   cortical AChE activity, 4  
   memory impairment in, 2  
   midfrontal ChAT activity, 4  
   treatment, 3–6  
   visuospatial function in, 2–3  
 Psychosis, 2, 11  
 PTEN (protein tyrosine phosphatase with homology to tensin) gene, 13  
 Putative neuroprotective therapies, 37  
 Pyramidal signs, 76  
 Quinine oxidoreductase, 362  
 Rapamycin, 292  
 Rapid-eye-movement (REM) sleep disturbances, 3, 38, 43, 78  
 Rasagiline analogs, 441  
 Rat neuronal cells, Wnt receptors and Frizzled expression in, 317–322  
 Receptor for advanced glycation end-products (RAGE), 193  
 Rehabilitation for PD  
   basic requirements for, 25  
   clinical research on, 24  
   cognitive rehabilitation, 27  
   limitations of, 27–28  
   neurophysiological approach to, 25–27  
   physiological strategies for motor problems in, 26  
   problems in, 25  
   symptomatic dopaminergic treatment, 23  
 Resting tremor, 25, 76, 78, 80, 82, 85, 159  
 Restless legs syndrome, 41  
 Resveratrol, neuroprotective effects against A $\beta$ -induced toxicity, 293  
 Retinoic acid, 18  
    $\alpha$ -secretase pathway up-regulation by, 371–373  
 Reverse transcription polymerase chain reaction (RT-PCR), 93  
 Rho/JNK planar cell polarity pathway, 319

- Rivastigmine, 4–6, 405, 439–441  
 ROCO proteins, 14, 82–83  
 Rotenone models of PD, 36, 60–62, 138
- Sagamihara family with LRRK2 gene,  
 clinical and pathological  
 description of, 75, 84–85
- Sandhoff disease, 227  
 SAP-2 deficiency, 227  
 SAP precursor deficiency, 227  
 SBE-luc reporter mice, 176–178  
 bioluminescent imaging of excitotoxic  
 brain In, 179  
 noninvasive imaging of endotoxic brain  
 injury *in vivo*, 179–181  
 specificity of, 177–178
- Schizophrenia, 158, 317
- $\alpha$ -Secretase, 439  
 ADAM10 as, 369–370, 394  
 pathway up-regulation, 369–373  
 downstream signaling systems,  
 370–371  
 G protein-coupled receptors  
 activation, 370–371  
 human ADAM10 promoter and,  
 371–373  
 PACAP-induced activation, 371–342  
 by retinoic acid, 371–373  
 processing and  $\beta$ -APP and TSEs,  
 305–308, 310, 312
- $\beta$ -Secretase, 124, 305, 311, 369, 439  
 $\gamma$ -Secretase, 124, 223, 305, 369, 394, 439
- Secreted APP (sAPP), 259–262  
 Selegiline [(-)-deprenyl], 41  
 Senile dementia, 191  
 Senile plaques (SPs), 123, 375  
 Sepsis, 32  
 Sequence effect, 26–27  
 Serin palmitoyltransferase (SPT), inhibition  
 of, 222  
 Serotonin transporters (SERT), 60  
 Single-chain antibodies (ScFvs),  
 273–277
- Single photon emission computed  
 tomography (SPECT), 36, 40
- SK-N-MC cells, *see* Human neuroblastoma  
 (SK-N-SH) cells
- Smad-binding elements (SBEs), 175–176,  
 179–180
- Smad proteins, 175, 179  
 Smad1 proteins, 175  
 Smad2 proteins, 175, 179  
 Smad3 proteins, 175, 179
- Smad5 proteins, 175  
 Smad8 proteins, 175  
*SNCA*, mutations in, 171  
 $\gamma$ -Soluble NSF attachment protein (SNAP),  
 156, 158
- Sphingomyelinase, 227  
 Sphingomyelin (SM), 223  
 Spongiform encephalopathies, 231–232  
 Sporadic frontotemporal dementias, 231  
 Sporadic PD, 12, 14, 35, 57, 67, 83, 97,  
 127–128
- Statistical parametric mapping (SPM)  
 method, 188
- Stem cell biology, APP function in, 259–262  
 Stem cell therapy in AD, 255–262  
 dedifferentiation, 258–259  
 selection, 256  
 transdifferentiation, 256–258
- Stereotactic surface projections (SSP)  
 method, 188
- Stress-activated protein kinase (SAPK), 295
- Subcutaneous rotenone exposure models  
 of PD, 62
- Substantia nigra (SN), 36–37, 40, 43, 117,  
 128, 134, 137–138
- Sulfated glycosaminoglycans (sGAGs), 232  
 biosynthesis of, 232–233  
 interactions with  
 $\beta$ -amyloid peptide, 233–235  
 prion protein and peptides, 235–237  
 $\alpha$ -synuclein, 235–237  
 tau protein and peptides, 235  
 therapeutic implications, 237–241
- Sulfatidase activator deficiency, 227  
 Sulfotransferase, 362  
 Superoxide dismutase, 362  
 Supranuclear gaze palsy, 85–86  
 SwissProt, 154
- Sympathetic ganglion cells, 51  
 Synaptic integrity and plasticity, 213–214  
 Synaptic plasma membranes (SPMs),  
 390–391
- Synaptic scaling, cholinergic neurons role in,  
 433–434
- Synaptophysin, 405  
 Synphilin-1 protein, 11  
 Synucleinopathies, 3, 38, 126–129, 231  
 $\alpha$ -Synuclein proteins, 9–10, 35, 40, 58, 61  
 Interactions with sGAGs, 235–237  
 models of PD, 66–67
- $\alpha$ -Synuclein (*SNCA*) gene, 9–10, 12, 63,  
 66–67, 76, 97–109, 123, 126–129,  
 133, 137–142, 159–160, 232

- Synucleopathies, 34  
 SYPRO ruby-stained spots, 151
- TACE, 309–312  
 Tacrine, 4, 441, 447
- Tau  
 phosphorylation, 125–126  
   intau<sup>VLW</sup>/GSK3 transgenic mice, 338–340  
   in tau<sup>VLW</sup>/APP<sup>SW</sup> transgenic mice, 339–340  
 polymerization and neurodegeneration, 337–340  
 protein interactions with sGAGs, 235
- Tauopathies, 79, 88, 108, 126, 129, 133, 140–142, 231, 375  
 and Alzheimer's disease, 124–126  
 cell models, 325–334  
   aggregation and toxicity, 330  
   aggregation of tau in cells, 327–329  
   cell lines, 326–327  
   fragmentation of tau<sub>RD</sub> by thrombin-like protease, 329–330  
   inhibition of aggregation by small molecule inhibitors, 331–333
- Tau<sub>RD</sub>  
 aggregation and toxicity, 330, 333–334  
 expression and aggregation, 327–330  
 cell toxicity of, 330, 333–334  
 inhibition small molecule inhibitors, 331–333  
 inhibition in vitro, 331  
 kinetics of, 328–329  
 reversibility, 331  
 fragmentation by thrombin-like protease, 329–330
- Tau<sup>VLW</sup>/APP<sup>SW</sup> transgenic mice, tau phosphorylation in, 339–340  
 Tau<sup>VLW</sup>/GSK3 transgenic mice, tau phosphorylation in, 338–340
- Tay-Sachs disease, 227  
 T-cell factor (TCF), 318  
 Tea extracts, hippocampal neurons  
   protection by, 293
- Ten Point Clock-Drawing test, 5  
 Tensor-based morphometry (TBM)  
   methods, 187
- Tet-On system, 325, 327  
 1,2,3,4-Tetrahydro-isoquinolines, 36  
 Tg2576 APP transgenic mice, 265, 268  
 TgCRND8 transgenic model, 395  
 Tg2576 mice, 431
- Thiobarbituric acid reactive substance (TBARS), 150  
 Thioflavin-S staining, 275, 414, 418  
 Thiol methyltransferase, 362  
 Thiopurine methyltransferase (TPMT), 362  
 Thorn-shaped astrocytes (TSAs), 375–379  
   evaluation of 4R tauopathy and, 377  
   frequency in AD, 377–379  
   immunohistochemistry, 376–377  
   relation with 4R tau score in AD, 378
- Thrombosis, 32  
 Th1 T cells, 269–270  
 Th2 T cells, 269–270
- Transcranial ultrasonography, for PD  
   detection, 40
- Transcription actors of FoxO family, trophic factors effects on, 292
- Transforming growth factor- $\beta$ 1 (TGF $\beta$ 1)  
   protein, 175–179
- Transforming growth factor- $\beta$ 2 (TGF $\beta$ 2)  
   protein, 175, 177, 179
- Transforming growth factor- $\beta$ 3 (TGF $\beta$ 3)  
   protein, 175, 177, 179
- Transforming growth factor- $\beta$  (TGF $\beta$ )  
   proteins, 53–54, 175–179
- Transgenic *Drosophila*, 66
- Transmissible spongiform encephalopathies (TSEs), 305  
   physiological processing, 305–312  
     ADAM9 and, 305, 311–312  
     ADAM10 and, 305, 309–313  
     ADAM17 and, 305, 309–310  
     up-regulation by PKC agonists, 307–309  
    $\alpha$ -secretase processing, 305–308
- Traumatic brain injury, 135, 137  
 Trimethylamine N-oxidase, 362  
 Triose phosphate isomerase (TPI), 156  
 TrkB receptors, 279, 285–289
- Trophic factors  
   effects on transcription actors of FoxO family, 292  
   neuroprotective effects of, 291–295
- $\beta$ -Tubulin, 405–406  
 Tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), 92–94, 309  
 TV3326 [-ethyl methyl carbamate], 442  
 TV3279 [-ethyl methyl carbamate], 442
- Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), 151  
 Tyrosine hydroxylase (TH) protein, 61, 92  
 Tyrosine kinase, 83, 128

- Ubiquitin-activating enzyme (E1), 10
- Ubiquitin-conjugating enzyme (E2), 10
- Ubiquitin C-terminal hydrolase isozyme L1 (Uch-L1), 12, 58, 64–65, 76, 97, 156–157
- Ubiquitin proteasome (UP) system, 10, 58, 63, 69, 334
  - inhibition cause of PD, 67–68
- Ubiquitin-protein ligase (E3), 10, 57, 137
- UDP-glucuronosyltransferases, 362
- Unified Parkinson Disease Rating Scale (UPDRS), 32–33, 36
- Unified Parkinson Disease Rating Scale (UPDRS) Part III, 5–6
- Uridine 5'-triphosphate glucuronosyl transferases (UGTs), 362
- Urinary urgency, 11
  
- Vascular endothelial growth factor (VEGF), 53
- VDAC-1, 156
- Vertical gaze palsy, 76
- Vesicular acetylcholine transporter (vAChT), 286, 432
- Vesicular glutamate transporter (VGLUT1), 406
  
- Vision tests, for PD detection, 41
- Visuospatial function, 2–3
- Vitamin C, 136–137
- Vitamin E, 136–137, 155, 454
- Volume of interest analyses (VOI) method, 188
- Von Economo encephalitis lethargica, 36
- Voxel-based morphometry (VBM) methods, 187
  
- Wild-type C57BL/6J mice, 344–351
  - F4/80-positive microglia, 345, 348–351
  - IL-1 $\beta$ -positive cells, 345–348, 351
  - immunohistochemistry, 345
  - intracerebroventricular injection of LPS, 344
  - mac-2-positive microglia, 345, 348–351
  - NF- $\kappa$ B-positive cells, 345–348, 350–351
- Wnt/Ca<sup>2+</sup> pathway, 319
- Wnt receptors expression, in rat neuronal cells, 317–322
  
- Xenogeneic monkey brain, PC12 cells grafting to, 52
- 3xTg-AD mice, 298, 300–301
  
- Yapsin, 309